Menu
Recruiting NCT04664686

Rate or Rhythm Control in CRT: the RHYTHMIC Study

No phase Interventional Atrial Fibrillation Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AF catheter ablation, AV node ablation.
Who it may be relevant to
Registry conditions: Atrial Fibrillation, Heart Failure. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

70 patients with heart failure, AF and CRT with BiV\<95% will be randomised to either AF ablation or AV node ablation. Evaluation at 6 months with echocardiography and clinical assessment.

Detailed description

70 patients with heart failure, AF and CRT with BiV\<95% will be recruited from outpatient clinic, pacing clinic or inpatient wards. Patients will be consented and will undergo baseline investigation with a transthoracic 2D echocardiogram, ECG, blood tests, cardiac CT with perfusion imaging, 6 minute walk test (6MWT), cardio-pulmonary exercise test (CPET) and Minnesota Living with Heart Failure Questionnaire. Patients who are successfully screened will be randomized 1:1 to receive AF catheter ablation rhythm control or AV-node ablation rate control.

Ablation Procedure:

Patients will receive either AF catheter ablation or AV-node ablation during the procedure. Patients randomised to AF catheter ablation will receive isolation of all four pulmonary veins and additional lesions, considered indicated by the operator. The procedure will be classified as successful if all four veins are isolated and the patient is in sinus rhythm. Patients may undergo DC-cardioversion under sedation if they remain in atrial fibrillation. AV-node ablation will be performed in line with current standard of care. Patients will also undergo additional research investigations at the time of ablation as follows:

Acute Haemodynamic Study:

All patients will also undergo an acute haemodynamic study with pressure wire assessment of both the right ventricle and the left ventricle at the start and end of the procedure. This involves inserting pressure wires into the RV via a vein in the groin and into the LV via an artery in the wrist or the groin. This will provide novel information on how AF catheter ablation and AV-node ablation affect cardiac contractility.

Invasive Electroanatomical Mapping (Optional):

This is an optional additional procedure that patients may opt into at the time of recruitment. This is performed during the ablation procedure with mapping catheters and software which are CE marked and already in clinical use. Mapping of all four cardiac chambers will be performed. This will be achieved via a vein and an artery in the groin. This will provide novel information on how AF catheter ablation and AV-node ablation affect electrical activation of the atria and ventricles.

Follow-up:

Patients will undergo a 2D transthoracic echocardiogram and ECG 1 week post ablation. Patients will then be followed up at 6 months with 2D transthoracic echocardiogram, ECG, clinical review, CPET, 6MWT, Minnesota Living with Heart Failure Questionnaire and pacing check.

Patients in the AF catheter ablation group who have a recurrence of AF after a 3 month blanking period will be permitted a re-do procedure. The follow-up investigations will take place 6 months after the re-do procedure. If a patient has recurrence of AF after a second ablation procedure and it is felt a third procedure is indicated, this will be performed after the six month follow-up period has ended and the patient is no longer in the study. They will be included in the intention-to-treat analysis.

Interventions

  • Procedure AF catheter ablation
    Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
  • Procedure AV node ablation
    AV node ablation

Primary outcome measures

  • Difference in ejection fraction [Time frame: 6 months]
Secondary outcome measures (8)
  • Difference in left ventricular end systolic volume [Time frame: 6 months]
  • Difference in biventricular pacing percentage [Time frame: 6 months]
  • Difference in quality of life [Time frame: 6 months]
  • Difference in NYHA class [Time frame: 6 months]
  • Difference in heart failure symptoms [Time frame: 6 months]
  • Difference in 6-minute walk test [Time frame: 6 months]
  • Difference in VO2 max [Time frame: 6 months]
  • Difference in AF burden [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Ability to provide informed consent to participate and willing to comply with the clinical investigation plan and follow-up schedule.
  • QRS duration >120ms on surface ECG, severe left ventricular systolic impairment (EF≤35%) and clinical symptoms of heart failure despite optimum medical therapy (NYHA class II-IV) at time of CRT implant or upgrade
  • Successful CRT implant or upgrade including atrial lead
  • Biventricular pacing percentage <95% secondary to atrial fibrillation at least 3 months post implant or upgrade
  • Clinically indicated for AV node ablation

Exclusion criteria

  • Life expectancy <1 year
  • Presence of atrial or ventricular thrombus
  • Permanent atrial fibrillation
  • Mechanical aortic valve replacement
  • Severe peripheral vascular disease
  • Female participants who are pregnant, lactating or planning pregnancy during the course of the study.
  • Participation in other studies with active treatment / investigational arm

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United Kingdom · 1 center
  • Guys and St Thomas' NHS Foundation Trust — London

Identifiers

NCT: NCT04664686 · 265388

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗